Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine

We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high‐risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI) <80% on the overall survival (OS). There were 51.6% of patients who had full dose and 48.4% had d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Med
Asıl Yazarlar: Laribi, Kamel, Bolle, Delphine, Alani, Mustafa, Ghnaya, Habib, Besançon, Anne, Farhi, Jonathan, Mheidly, Kayane, Denizon, Nathalie, Baugier de Materre, Alix
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2019
Konular:
Clinical Cancer Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6536936/
https://ncbi.nlm.nih.gov/pubmed/30993891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2121
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller